Clinical Trials Logo

Hydatidiform Mole clinical trials

View clinical trials related to Hydatidiform Mole.

Filter by:

NCT ID: NCT05637892 Not yet recruiting - Hydatidiform Mole Clinical Trials

A Cohort Study of Hydatidiform Mole

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this study is to construct a cohort for the hydatidiform mole.

NCT ID: NCT05516810 Active, not recruiting - Missed Abortion Clinical Trials

The Accuracy of Ultrasound Diagnosis of Hydatidiform Moles

Start date: October 19, 2021
Phase:
Study type: Observational

This is a prospective observational study assessing which ultrasound findings are best at excluding a molar pregnancy in first trimester miscarriage.

NCT ID: NCT04756713 Recruiting - Clinical trials for Gestational Trophoblastic Neoplasia

Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia

ReCure
Start date: February 11, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of second uterine curettage in patients with low-risk non-metastatic GTN.

NCT ID: NCT03785574 Recruiting - Clinical trials for Gestational Trophoblastic Neoplasia

Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule

Start date: December 24, 2018
Phase: N/A
Study type: Interventional

The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). Lung nodule <1.0cm will directly treated as group C

NCT ID: NCT02892877 Recruiting - Hydatidiform Mole Clinical Trials

The French National Reference Centre of GTD

French GTDC
Start date: November 1999
Phase: N/A
Study type: Observational [Patient Registry]

The French Gestational Trophoblastic Disease (GTD) centre has been set up and active by registering, monitoring and treating women with GTD since november 1999. The aim is to improve the management of trophoblastic disease in France. About 850 new cases are registered each year and 140 women treated, mostly with chemotherapy and surgery. The center works as follow, based on a multidisciplinary approach. The policy is that patient remains followed by her local physician, but can be seen and treated in the Center at demand and that the registry is done on a voluntary basis. Each administrative french area has a local expert team (oncologist and gynaecologist) who is able to look after the patients with the help of the national reference center physicians based in Lyon. - Once a doctor discovers a molar pregnancy, he contacts the center, with the agreement of his patient, for an opinion, an advice or simply to report the case. - The center sends to the doctor the informed consent form to be signed by the patient, a registering form and information about pathology for patient and physician, and first guidelines based on initial pathology report. The patient remains followed by her gynecologist, who stays her first interlocutor throughout the whole process and she goes to her local laboratory for hCG monitoring; - A letter is sent to the initial pathology laboratory that originally carried the diagnosis of molar pregnancy to require slide sending to the pathologist referral center (9 experts with a specific pathologist national network) that centrally review initial diagnosis. - In the mean time, the data manager collects weekly hCG values to establish a follow-up chart. The physician is regularly informed by mail of the hCG evolution. - The local physician is contacted in case of modification of the diagnosis by the pathologist expert. The center informs him about length and monitoring methodology. - Emails or letters are sent at each step of the management (at inclusion, at hCG negativation, and at the end of hCG follow-up). - In case of abnormal hCG evolution (raise, plateauing or positivity at 6 months,) or if a neoplasia is anatomopathologically diagnosed (choriocarcinoma, PSTT or ETT), physician is immediately contacted by phone or email by referent gynaecologist. A complete work up including pelvic US with Doppler, pelvic MRI, thoraco-abdominal CT-scan with chest radiography if pulmonary nodules are present and brain MRI, is planned to determine the adequate treatment. Very briefly, based on imaging results, FIGO stade and score are calculated to determine the risk. In case of low-risk, a monochemotherapy is settled, while a polychemotherapy is started in case of high-risk disease. The investigators have developped specific expertise at key levels of diagnosis, management, follow-up, fertility preservation and treatment. Assignments : - Registration and monitoring post diagnosis of complete or partial molar pregnancy, choriocarcinoma,PSTT, ETT, atypical placental site nodules - Histopathological analysis and genetics services - Measurement of human chorionic gonadotrophin (hCG) isoforms - Complex gynaecological surgery

NCT ID: NCT01984099 Completed - Hydatidiform Mole Clinical Trials

RCT on the Efficacy of Methotrexate for the Prevention of GTD

Start date: December 2011
Phase: Phase 3
Study type: Interventional

A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.

NCT ID: NCT01630954 Recruiting - Hydatidiform Mole Clinical Trials

A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole

Start date: June 2012
Phase: Phase 4
Study type: Interventional

Hydatidiform mole is a common complication of pregnancy with an incidence of 1in 400 pregnancies in India. Although this is a benign condition , it is having the malignant potential too. A repeat curettage after evacuation of hydatidiform mole was generally advocated till 1990s. A thorough curettage at the time of initial evacuation was not performed because of larger size of uterus and risk of perforation. Subsequently a number of studies assessed the usefulness of repeat curettage and found it was unnecessary and not cost effective . However all these studies are retrospective in design and conducted in developed countries where hydatidiform mole is diagnosed earlier because of wider use of ultrasonography. Thus there is a need to perform a well designed prospective study to compare the effectiveness of single evacuation with double evacuation in treatment of hydatidiform mole for prevention of Gestational Trophoblastic Neoplasia.This study compares the effectiveness of single evacuation versus double evacuation for treatment of hydatidiform mole for prevention of gestational trophoblastic neoplasia .

NCT ID: NCT01535053 Completed - Choriocarcinoma Clinical Trials

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

Start date: June 18, 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. Drugs used in chemotherapy, such as methotrexate and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether methotrexate is more effective than dactinomycin in treating gestational trophoblastic disease.

NCT ID: NCT01008501 Active, not recruiting - Hydatidiform Moles Clinical Trials

Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles

Start date: November 7, 2000
Phase:
Study type: Observational

The researchers' laboratory is studying a rare class of highly recurrent hydatidiform moles. These are usually complete hydatidiform moles (CHM), but sometimes they are partial hydatidiform moles PHM). With sporadic moles, the difference between CHMs and PHMs is that with CHMS, there is not typically an embryo or fetus at the time of diagnosis but with a PHM there may be a fetus. Also, CHMs have 46 chromosomes in each cell. While this is the number of chromosomes that should be found, the problem is that all the chromosomes come from the father. Normally, half the chromosomes should come from the mother and half should come from the father. Unlike CHMs, PHMs have 69 chromosomes. This means that PHMs have three copies of each chromosome when they should only have two. The extra copy comes from the father. The researchers' study focuses on moles that are genetically different from these sporadic moles in that they have 23 chromosomes from the mother and 23 chromosomes from the father - just like a normally developing pregnancy. These are called biparental moles because the mutation that causes the mole comes from both parents. This mutation occurs in a gene called NLRP7. The researchers' team is working to understand how mutations in NLRP7 leads to CHMs and how these mutations may lead to other types of pregnancy loss. The researchers are also trying to discover other genetic and epigenetic factors that may lead to moles.

NCT ID: NCT00521118 Completed - Clinical trials for Non-Metastatic Gestational Trophoblastic Tumor

Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

Start date: October 9, 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well a second curettage (removal of the abnormal cancer cells in the uterus using a method of surgically removing the lining of the uterus) works in treating patients with gestational trophoblastic tumors that did not go away after a first curettage (persistent) and has not yet spread to other places in the body (non-metastatic). A second curettage may be effective in treating persistent gestational trophoblastic tumors and may decrease the likelihood that patients will need chemotherapy in the near future.